Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CSX1004
- Development stage
- Phase 1
- Lead developer
- Cessation Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Intramuscular
01
Overview
CSX1004 is a fully human monoclonal antibody designed for the treatment and prevention of fentanyl-related drug overdoses. Developed by Cessation Therapeutics using OmniAb's transgenic rat platform (OmniRat), the antibody acts as a high-affinity sequestering agent in the bloodstream. By binding specifically to fentanyl and its potent analogs, CSX1004 prevents these synthetic opioids from crossing the blood-brain barrier and interacting with mu-opioid receptors in the central nervous system. This mechanism is intended to reverse respiratory depression and provide a prolonged period of protection against re-intoxication, addressing the limitations of short-acting antagonists like naloxone in the context of long-lasting synthetic opioids.
- Other names
- anti-fentanyl monoclonal antibody
Beyond the preview
Go deeper on CSX1004.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CSX1004.